RGCP .195 float 284 k, from filing yestereday
On June 20, 2018, the Company entered into a Subscription and Securities Purchase Agreement (the “SPA”) with three investors. Under the SPA, the investors will be issued a (collectively) controlling interest in the Company consisting of a total of 484,766,388 shares of common stock. These shares will be issued in exchange for a total Purchase Price of $95,000. Under the SPA and its related agreements, the Purchase Price will be used to settle and retire our notes payable, for certain compliance costs, and for general working capital. In conjunction with the SPA, our controlling shareholder, Biodynamic Molecular Technologies, LLC, will exchange its preferred stock for a total of 13,465,733 shares of common stock. This common stock position, which will represent 2.5% of our post-closing common stock, will be non-dilutable for a period of one (1) year. The SPA and its related agreements are expected to close in the near future.
